A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

September 21, 2026 updated by: Novartis Pharmaceuticals

A 24-week Prospective, Open-label, Multicenter, Single-arm Regulatory Post-Marketing Surveillance (rPMS) Study in Real-world Setting (Mandatory by Local HA Regulation) for Atectura® (QMF149 150/80 μg o.d., QMF149 150/160 μg o.d. and QMF149 150/320 μg o.d. Via Breezhaler)

This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Atectura inhalation capsule for up to 24 weeks under routine clinical practice.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The three different doses of Atectura inhalation capsule via Breezhaler will be prescribed according to the approved label information in Korea, and the investigation for any additional diagnostic or monitoring will be not conducted for this study

Study Type

Observational

Enrollment (Actual)

670

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Busan, South Korea, 48108
        • Novartis Investigative Site
      • Gyeongsangnam Do, South Korea, 51353
        • Novartis Investigative Site
      • Jeju City, South Korea, 63241
        • Novartis Investigative Site
      • Seoul, South Korea, 05505
        • Novartis Investigative Site
      • Seoul, South Korea, 04763
        • Novartis Investigative Site
      • Seoul, South Korea, 06273
        • Novartis Investigative Site
      • Seoul, South Korea, 137 707
        • Novartis Investigative Site
      • Taegu, South Korea, 41944
        • Novartis Investigative Site
      • Ulsan, South Korea, 44033
        • Novartis Investigative Site
    • Dalseo gu
      • Daegu, Dalseo gu, South Korea, 42602
        • Novartis Investigative Site
    • Gangneung si
      • Kangwon Do, Gangneung si, South Korea, 210 711
        • Novartis Investigative Site
    • Gangwon-do
      • Wŏnju, Gangwon-do, South Korea, 26426
        • Novartis Investigative Site
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, South Korea, 10380
        • Novartis Investigative Site
      • Guri-si, Gyeonggi-do, South Korea, 11923
        • Novartis Investigative Site
    • Gyeongsangnam-do
      • Jinju, Gyeongsangnam-do, South Korea, 52727
        • Novartis Investigative Site
    • Jeollabuk-do
      • Jeonju, Jeollabuk-do, South Korea, 54907
        • Novartis Investigative Site
    • Jeonlabuk Do
      • Iksan Si, Jeonlabuk Do, South Korea, 54538
        • Novartis Investigative Site
    • Korea
      • Daejeon, Korea, South Korea, 35015
        • Novartis Investigative Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

12 years to 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

subjects who received at least one dose of Atectura inhalation capsule via Breezhaler and that have provided consent for their data collection.

Description

Inclusion Criteria:

  1. Adolescent (≥12 years of age) and adult patients with a physician's diagnosis of asthma, who are prescribed Atectura inhalation capsule (indacaterol acetate/mometasone furoate; 150/80, 150/160, 150/320 μg) via Breezhaler, as per the approved label information
  2. Patients who participate in the study after signing the consent form for data collection and use (Data Privacy ICF) after receiving a clear explanation of the objectives and nature of the study from the investigator (For patients under the age of 18, consent and signature of a legal representative is required)

Exclusion Criteria:

  1. Patients who are contraindicated for this medicinal product as described in the Precautions for Use in the label information (package insert) A. Patients with hypersensitivity reaction to this medicinal product or any of its constituents B. Because this medicinal product contains lactose, patients with hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption, etc.
  2. Patients with acute asthma symptoms, including acute episodes of bronchospasm, for which a short-acting bronchodilator is required
  3. Patients participating in other interventional clinical trials

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Atectura inhalation capsule (150/80ug)

Indacaterol acetate/Mometasone furoate; 150/80ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/160ug)

Indacaterol acetate/Mometasone furoate; 150/160ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

Atectura inhalation capsule (150/320ug)

Indacaterol acetate/Mometasone furoate; 150/320ug

There is no treatment allocation. Patients administered Atectura by prescription that have started before inclusion of the patient into the study will be enrolled.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of adverse events and serious adverse events
Time Frame: 24 weeks

Incidence of AE and SAE will be collected

24 weeks
Incidence of unexpected adverse events and unexpected serious adverse events
Time Frame: 24 weeks

Incidence of unexpected AE and SAE will be collected. The term "unexpected" means not listed in local label

24 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change from baseline in trough FEV1
Time Frame: Baseline, week 12

Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer.

Baseline, week 12
change from baseline in ACT score
Time Frame: Baseline, week 12

The Asthma Control Test (ACT) is a validated tool to assess overall asthma control. It is a 1 page questionnaire consisting of 5 simple questions assessing: asthma symptoms, use of rescue medications, and the impact of asthma on everyday functioning. All questions are scored on a 5-point Likert scale, with a higher score indicating better control. All scores are added together to calculate a total score. Total score ranges from 5 to 25. A positive change indicates improvement.

Baseline, week 12
Effective rate and ineffective rate by investigator assessment
Time Frame: week 12

Effective (improved) rate and ineffective (unchanged/aggravated) rate by investigator assessment

week 12
Baseline characteristics of patients showing adverse events/adverse drug reactions
Time Frame: 24 weeks

The incidence rates of AEs/ADRs will be presented by factors, such as subject baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

24 weeks
Baseline characteristics of patient in relation to changes from baseline through FEV1 and ACT score
Time Frame: 12 weeks

Regression analysis will be performed to determine factors affecting the change in trough FEV1 and ACT score, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations

12 weeks
Baseline characteristics of patients in relation to the investigator assessment
Time Frame: 12 weeks

Logistic regression analysis will be performed to determine factors affecting the effectiveness (improved) in the investigator assessment, out of baseline characteristics (age (<65 vs. ≥65 years), male vs. female, pregnancy (yes vs. no), family history (yes vs. no), exacerbation history (0 vs. above 1), smoking history (yes vs. no), comorbidity (yes vs. no), concomitant medication/ therapy (yes vs. no)), study treatment information, and special populations.

12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 9, 2022

Primary Completion (Estimated)

December 24, 2026

Study Completion (Estimated)

December 24, 2026

Study Registration Dates

First Submitted

November 30, 2021

First Submitted That Met QC Criteria

January 19, 2022

First Posted (Actual)

February 1, 2022

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 21, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • CQMF149EKR01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.